Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L McCullough

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Brachytherapy|April 6, 2004
Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapyRex A Kiteley, W Robert Lee, Allan F deGuzman, et al.
Brachytherapy|October 22, 2008
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alonePeter J Rossi, James Urbanic, Peter E Clark, et al.
Urology|February 8, 2006
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerPeter J Rossi, Peter E Clark, Michael A Papagikos, et al.
Cancer Research|February 12, 2004
Deficient nucleotide excision repair capacity enhances human prostate cancer riskJennifer J Hu, M Craig Hall, Lawrence Grossman, et al.
Brachytherapy|December 14, 2005
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?Michael A Papagikos, Allan F Deguzman, Peter J Rossi, et al.
American Journal of Clinical Oncology|April 7, 2007
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy aloneMichael A Papagikos, Peter J Rossi, James J Urbanic, et al.
Nature Genetics|September 24, 2002
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer riskJianfeng Xu, S Lilly Zheng, Akira Komiya, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Brachytherapy|April 6, 2004
Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapyRex A Kiteley, W Robert Lee, Allan F deGuzman, et al.
Brachytherapy|October 22, 2008
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alonePeter J Rossi, James Urbanic, Peter E Clark, et al.
Urology|February 8, 2006
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerPeter J Rossi, Peter E Clark, Michael A Papagikos, et al.
Cancer Research|February 12, 2004
Deficient nucleotide excision repair capacity enhances human prostate cancer riskJennifer J Hu, M Craig Hall, Lawrence Grossman, et al.
Brachytherapy|December 14, 2005
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?Michael A Papagikos, Allan F Deguzman, Peter J Rossi, et al.
American Journal of Clinical Oncology|April 7, 2007
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy aloneMichael A Papagikos, Peter J Rossi, James J Urbanic, et al.
Nature Genetics|September 24, 2002
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer riskJianfeng Xu, S Lilly Zheng, Akira Komiya, et al.
Pageof 2